Device Trial Radar · NCT05567666
Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 7, 2023
Primary completion
Sep 5, 2025
Study completion Sep 5, 2025
Sponsor
- Lead sponsor
- Dean EltermanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Urotronic Inc.
- First posted
- Oct 5, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A post-marketing study using Optilume Catheter System for benign prostatic hyperplasia.
Conditions
- Benign Prostatic Hyperplasia
Interventions
Optilume Catheter SystemDevice
Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Responder Rate at 12 monthsTime frame: 12 months post treatment
- Safety (adverse events)Time frame: Within 12 months post treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Health Network
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.